Anorexia in end-stage renal disease: pathophysiology and treatment

Bibliography

• BERGSTROM J: Appetite in CAPD. Perk Dial. Irk (1996) 16 (S1):S181–S184.
   Google Scholar
• •An excellent review of appetite disorders in dialysis patients.
   Google Scholar
• OWEN W LEW N, LUI Y, LOWRIE E, J: The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. N Engl. j Med. (1993) 329:1001–1006.
   PubMedGoogle Scholar
• AGUILERA A, SELGAS R, BAJO MA: La uraemica. Nefrologin (1998) 18:263–269.
   Google Scholar
• •A review of the mechanisms implicated in uraemic anorexia (Spanish).
   Google Scholar
• AGUILERA A, BAJO MA, DIEZ J et al: modulators alterations condition abnormalities in food intake behaviour of peritoneal dialysis (PD) patietis. Perk Dial. mt. (1999) 19(S1):559.
   Google Scholar
• BARKELING B, ROSSNER S, A: Methodological studies on single meal food intake characteristics in normal weight and obese men and women. Intl Obes. (1995) 19:284–290.
   PubMedGoogle Scholar
• •A visual analogue scale to measure the motivation to eat.
   Google Scholar
• STRICKER EM: Biological bases of hunger satiety: therapeutic implications. Num. Rev (1984) 42:333–340.
   Google Scholar
• •A review of normal hunger-satiety cycle control.
   Google Scholar
• PEIKIN SR: Role of cholecystokinin in the control of food intake. Castroenterol. Clin. N Am. (1989) 18:757–775.
   PubMed Web of Science ®Google Scholar
• ANDERSON GH, LI ETS, ANTHONY SP, NG LT, BIALIK R: Dissociation between plasma and brain amino acid and short-term food intake in the. Am. J. Physiol. (1994) 35:R1675–R1686.
   Google Scholar
• MAYER J: Regulation of energy intake and body weight: the glucostatic theory and the lipostatic hypothesis. Ann. NYA cad. Li. (1955) 63:15–43.
   PubMed Web of Science ®Google Scholar
• •Glucostatic and lipostatic hypothesis about the appetite control.
   Google Scholar
• MELLINKOFF SM, FRANKLAND M, BOYLE D, GREIPEL M: Relationship between serum amino acids concentration and fluctuantion in appetite. I Appl. Physiol. (1956) 8:535–538.
   PubMed Web of Science ®Google Scholar
• MAMOUN AH, ANDERSTAM B, SODERSTEN P, LINDHOLM B, BERGSTROM J: Influence of peritoneal dialysis solutions with glucose and amino acids on ingestive behavior in rat. Kidney Irk (1996) 49:1276–1282.
   PubMedGoogle Scholar
• BELLINGER LL, WILLIAMS FE, ROGERS QR, GIETZEN DW: Liver
   Google Scholar
• •• attenuate the hypophagia produced by an imbalanced acid diet. Physiol. Behav (1996) 59:925–929.
   Google Scholar
• MODAWER LL, ANDERSON C, GELIN J, LUNDHOLM KG: Regulation of food intake and hepatic protein synthesis by recombinant derivated cytokines. Am. Physiol. (1988) 254:G450–G456.
   Google Scholar
• DUBE MG, XU B, CROWLEY WR, KALRA PS, KARLA SP: Evidence that neuropetide Y is a physiological signal of normal food intake. Brain Res. (1994) 646:341–344.
   PubMedGoogle Scholar
• PLATA-SALAMAN C: Cytokines and feeding suppression: an integrative view from neurologic to molecular levels. Nutrition. (1995) 11(55):5674–5677.
   Google Scholar
• •Analysis of TNF-a, IL-1 and -6 effects on the appetite.
   Google Scholar
• MACDONALD C, RUSH D, BERNSTEIN K, MCKENNA R: Production of tumoral necrosis factor in hemodialysis. Nephron (1993) 65:273–277.
   PubMedGoogle Scholar
• KAPAS L, HONG L, CADY AB et al: Somnogenic, pyrogenic, and anorectic activities of tumor necrosis factor alpha and TNF-a fragments. Am. j Physiol. (1993) 263:R708–R715.
   Google Scholar
• DAUN JM, MCCARTHY DO: The role ofcholecystokinin in interleukin-l-induced anorexia. Physiol. Behav (1993) 54:237–241.
   PubMed Web of Science ®Google Scholar
• TREGET EE, YU YM, ZHONG S etal.: Role of interleukin 1 and tumor necrosis factor on energy metabolism in rabbits. Am. Physiol. (1988) 255:E760–E768.
   Google Scholar
• CANGIANO C, LAVIANO A, MUSCARITOLI M, MEGUID MM, CASCINO A, FANELLI FR: Cancer anorexia: new pathogenic and therapeutic insights. Nutrition. (1996) 12:S48–S50.
   Google Scholar
• •A review about the implications of tryptophan and serotonin in appetite control.
   Google Scholar
• BEVERLY JL, HRUPKA BJ, GIETZENDW, ROGERS QR: Timing and dose of amino acids injection into the prepyriform cortex influence food intake. Physiol. Behav. (1993) 53:899–903.
   PubMed Web of Science ®Google Scholar
• SQUADRITO E CALAPAI D, D etal.: Central serotonergic system involvement in the anorexia induced by NG-nitro-L-arginine, an inhibitor of nitric oxide synthase. Eur. j Pharmacol. (1994) 255:51–55.
   PubMedGoogle Scholar
• KUHN DM, ARTHUR R: Molecular mechanism of the inactivation of hydroxilase by nitric oxide: attack on critical sulfhydryls that spare the enzyme iron center. I Neurosci. (1997) 17:7245–7251.
   Google Scholar
• RITZ E, VILLANCE E NOWICKI M: The effect of malnutrition on cardiovascular mortality in dialysis patients: is L-arginine the Answer? Nephol. Dial. Transplant (1994) 9:129–130.
   Google Scholar
• AGUILERA A, CODOCEO R, SELGAS Retal.: Anorexigen (TNF-a, cholecystokinin) and orexigen (Neuropeptide 11) plasma levels in peritoneal dialysis (PD) patients: their relationship with nutritional parameters. Nephrol. Dial. Transpl. (1998) 13:1476–1483.
   Google Scholar
• MENGUID MM, YANG ZJ, GLEASON JR: The Gut-Brain Brain-Gut axis on anorexia: toward an undestanding of food intake regulation. Nutrition. (1996) 12(51):S57–S62.
   Google Scholar
• BRENNER D, BUCK M, FEITELBERG S, CHOJKIER M: Tumor necrosis factor alpha inhibits albumin gene expression in a murine model of cachexia. j Clin Invest. (1990) 85:248–255.
   PubMed Web of Science ®Google Scholar
• VALLANCE E LEONE A, CALVER A, COLLIER J, MONCADA S: Accumulation of an endogenous inhibitor nitric oxide synthesis in chronic renal failure. Lancet (1992) 339:572–575.
   PubMedGoogle Scholar
• ANDO T, DUNN AJ: Mouse tumor necrosis factor alpha increase brain tryptophan concentrations and norepinephrine metabolism while activating the HPA axis in nice. Neuroimmunomodogy (1999) 6:319–329.
   PubMed Web of Science ®Google Scholar
• AGUILERA A, BAJO MA, SELGAS R et al.: Plasma leptin levels in peritoneal dialysis (PD) patients: its relation with nutritional status, anorexia and obesity. j Am. Soc. Nephrol. (1997) 8:260.
   PubMedGoogle Scholar
• STENVINKEL P: Leptin-a new hormoneof definite interest for the nephrologist. Nephrol. Dial. Transplant (1998) 13:1099–1101.
   PubMedGoogle Scholar
• CONVERSE RL, JACOBSEN TN, TOTO RD et al.: Symphathetic overactivity in patients with chronic renal failure. N Engl. Med. (1992) 327:1912–1918.
   PubMed Web of Science ®Google Scholar
• ISSE T, UETA Y, SERINO R et at. Effects of leptin on fasting-induced inhibition of neural nitric oxide synthase mRNA in paravetricular and supraoptic nuclei of rats. Brain Res. (1999) 846:229–235.
   Google Scholar
• LAVIANO A, MEGUID MM, YANG ZJ, GLEASON JR, CANCIANO C, FANELLI: Cracking the riddle of cancer anorexia. Nutrition (1996) 12:706–710.
   PubMed Web of Science ®Google Scholar
• LINDHOLM B, ALVERSTRAND A, FORST P, BERGTROM J: Plasma and muscle amino acids during continuous ambulatory peritoneal dialysis. Kidney Int. (1989) 35:1219–1226.
   PubMedGoogle Scholar
• LAVIANO A, CANGIANO C, PREZIOSA I, RIGGIO O, CONVERSANO L, CASCINO A: Plasma tryptophan and anorexia in liver cirrhosis. Int. j Eating Disord. (1996) 21:181–186.
   Google Scholar
• SIASSI F, WANG M, KOPPLE JD, SWENDESEID ME: Plasma tryptophan levels and brain serotonin metabolism in chonically uraemic rats. I Num. (1977) 107:840–845.
   Google Scholar
• LEIBOWITZ SF, ALEXANDER JT: Hypothalamic serotonin in control of eating behavior, meal size, and body weight. Biol. Psychiatry (1998) 44:851–864.
   PubMed Web of Science ®Google Scholar
• BABB AL, FARRELL PC, UVELLI DA, SCRIBNER BM: Hemodialyzed evaluation by examination of solute molecular spectra. Tins. Am. Soc. Artif Intern. Organs (1972) 17:98–105.
   Google Scholar
• ANDERSTAM B, MAMOUN AH, SODERSTEN P, BERGSTROM J: Middle-sized molecules fraction from uraemic ultrafiltrate (UF) and normal urine inhibit ingestive behavior in the rat. I Am. Soc. Nephrol. (1996) 7:2453–2460.
   PubMed Web of Science ®Google Scholar
• MARCUS RG, COHN E, URIBARRI J: Middle molecule clearance does not influence protein intake in hemodialysis patients. Am. J. Kid. Dis. (1998) 31:491–494.
   PubMedGoogle Scholar
• KESHEVIAH PR, NOLPH KD, VAN STONE JC: The peak concentration hypothesis: a urea kinetic approach to comparing the adequacy of continuous ambulatory peritoneal dialysis (CAPD) and hemodialysis. Pent. Dial. Int. (1989) 9:257–260.
   PubMedGoogle Scholar
• ••Hypothesis explaining uraemic toxicitythrough the variable concentration of urea and other toxins at peak (HD patients and a high but stable concentration for PD patients).
   Google Scholar
• HEIMBURGER O, TRANAEUS A, BERGSTROM J, LINDHOLM B: The effect of increased PD on KT/V: protein catabolic rate (PCR) and serum albumin. Pent. Dial. Int. (1992) 12(S1):519.
   Google Scholar
• STENVINKEL P, HEIMBORGER O, LINDHOLM B, KAYSEN G, BERSGTROM J: Are there two types of in chronic renal failure? Evidence for relationship between malnutrition, inflammation and atherosclerosis (MIA syndrome). Nephrol Dial. Transplant (2000) 15:953–960.
   PubMed Web of Science ®Google Scholar
• ••Hypothesis explaining the link betweenmalnutrition, atherosclerosis and inflammation in dialysis patients.
   Google Scholar
• BOLOGA RM, LEVINE DM, PARKER TS et al.: Interleukin-5 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am. J. Kidney Dis. (1998) 32:107–114.
   PubMed Web of Science ®Google Scholar
• MENDALL MA, PATEL E BALLAM L, STRACHAN D, NORTHFIELD TC: C-reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study. Br. Med. J. (1996) 312:1061–1065.
   PubMed Web of Science ®Google Scholar
• STENVINKEL E LINDHOLM B, HEIMBORGER M, HEIMBORGER 0: Elevated serum levels of soluble adhesion molecules predict death in pre-dialysis patients: association with malnutrition, inflammation, and cardiovascular death. Nephrol Dial. Transplant (2000) 15:1624–1630.
   PubMedGoogle Scholar
• BISTRIAN BR: Role of the systemic inflammation response syndrome in the development of protein-calorie malnutrition in ESRD. Am. J. Kidney Dis. (1998) 32(S4):S113–117.
   Google Scholar
• AGUILERA A, SELGAS R, CODOCEO R, BAJO MA: Uraemic anorexia: a consequence of persistently high brain serotonin? The tryptophan/serotone disorder hypothesis. Pent. Dial. Int. (2000) 20:810–816.
   PubMedGoogle Scholar
• ••Tryptophaniserotonin hypothesisexplaining the pathogenesis of uraemic anorexia. Integrating the current knowledge about the factors responsible for appetite control and their influence on intracerebral serotonin.
   Google Scholar
• SULLIVAN PA, MURNAGHAN D, CALLAGHAN N, KANTAMANEMI BD, CURZON GD: Cerebral transmitter precursors and metabolites in advanced renal disease. J. Neural. Neurosurg. Psychiatry (1978) 41:581–588.
   PubMedGoogle Scholar
• NIEBAUER J, VOLK HD, KEMP M etal.: Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet (1999) 353:1838–1842.
   Google Scholar
• KAYE W, GENDALL K, STROBER M: Serotononin neural function and selective serotonin reuptake inhibitor treatment in anorexia and bulimia nervosa. Biol. (1998) 44:825–838.
   Google Scholar
• CANGIANO C, LAVIANO A, MEGUID MM etal.: Effects of administration of oral branched-chain amino acids on anorexia and caloric intake in cancer patients. J. Nat. Cancer Inst. (1996) 88:550–552.
   Google Scholar
• WATANABE S, BRUERA E: Anorexia and cachexia, asthenia, and lethargy. Hemat. arca Clin. N Am. (1996) 10:189–206.
   PubMed Web of Science ®Google Scholar
• LOPRINZI CL, ELLISON NM, SCHAID DJ et al.: Controlled trial of megestrol acetate for the treatment of cancer, anorexia and cachexia. j Nat. Cancer. Inst. (1990) 82:1127–1132.
   PubMed Web of Science ®Google Scholar
• LOPRINZI CL, SCHAID DJ, DOSE AN et al: Body-composition changes in patients who gain weight while receiving megestrol acetate. J Chu. arca (1993) 11:152–154.
   Google Scholar
• LOPRINZI CL, MICHALAK JC, SCHAID DJ: Phase three evaluations of four doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia.j Clin. arca (1993) 11:762–767.
   PubMed Web of Science ®Google Scholar
• LIEN YH, RUFFENACH SJ: Low dose megestrol increases serum albumin in malnourished dialysis patients. Int. J. Aral Organs (1996) 19:147–150.
   PubMedGoogle Scholar
• BURROWES JD, BLUESTONE PA, WANG J, PIERSON RN: The effects of moderate dose of megestrol acetate on nutritional and body composition in a hemodialysis patient. J. Ren. Num (1999) 9:89–94.
   PubMed Web of Science ®Google Scholar
• BOCCANFUSO JA, HUTTON M, MCALLISTER B: The effects of megestrol acetate on nutritional parameters in a population. J. Ren. Num (2000) 10:36–43.
   PubMedGoogle Scholar
• MONTALVINI G, MACCIO A, LAI P, MASSA E, GHIANI M, SANTONA M C: Cytokine activity in cancer-related anorexia/ cachexia: role of megestrol acetate and medroxiprogesterone acetate. Serail]. arca (1998) 25:45–52.
   Google Scholar
• MCCARTHY HD, CROWDER RE, DRYDEN S, WILLIAMS G: Megestrol acetate stimulates food and water intake in the rat: effects on regional hypothalamic neuropeptide Y concentration. Eur. Pharmacol (1994) 265:99–102.
   PubMed Web of Science ®Google Scholar
• TCHEKMEDYIAN NS, TAIT N, MOODY M, AISNER J: High-doses megestrol acetate. A possible treatment for cachexia. JAMA (1987) 257:1195–198.
   Google Scholar
• GRAHAM K, MIKOLICH DJ, FISHER AE, POSNER MR, DUDLEY MN: Pharmacologic evaluation of megestrol oral suspension in cachectic AIDS patients. J. Acquit Immune Defic. Syndr. (1994) 7:580–585.
   PubMed Web of Science ®Google Scholar
• CHARLTON MR: Branched chains revisited. Gastroenterology (1996) 111:252–255.
   PubMedGoogle Scholar
• FANELLI FR, CANGIANO C, CECI F et al.: Plasma tryptophan and anorexia in human cancer. Eur. J. Cancer Chit arca (1986) 22:89–95.
   Google Scholar
• CANGIANO C, LAVIANO A, MEGUID MM et al.: Effects of administration of oral branched-chain amino acids on anorexia and caloric intake in cancer patients. J. Nat. Cancer Inst. (1996) 88:550–552.
   PubMed Web of Science ®Google Scholar
• LAVIANO A, MEGUID M: Nutritional issues in cancer management. Nutrition. (1996) 12:358–371.
   PubMed Web of Science ®Google Scholar
• TESSARI P, ZANETTI M, BARAZZONI R et al.: Response of phenylalamine and leucine kinetics to branches chain-enriched amino acids and insulin in patients with cirrhosis. Castroenterol. (1996) 111:127–137.
   PubMedGoogle Scholar
• ESPINOZA M, AGUILERA A, BAJO MAetal.: Tumor necrosis factor alpha as a uraemic toxin: correlation with neuropathy, left vetricular hyperthrophy, anemia, and hypertriglyceridemia in peritoneal dialysis patients. Adv. Pent. Dial. (1999) 15:82–86.
   Google Scholar
• PRESENT DH, RUTGEERTS P, TARGAN S etal.: Infliximab for the treatment of fistulas in patients with chrohn disease. N Engl. J. Med (1999) 340:1398–1405.
   Google Scholar
• TERUEL JL, MARCEN R, NAVARRO J, A, FERNANDEZ-JUAREZ G, ORTUSIO J: Androgens versus erythropoietin for the treatment of anemia in hemodialyzed patients: a prospective study. J Am. Soc. Nephrol (1996) 7:140–144.
   PubMedGoogle Scholar
• •A unique comparative, prospective, controlled clinical research analysing the effects of erythropoietin versus ND in dialysis patients.
   Google Scholar
• BRADLEY J, ANDERSON J, EVANS D, COWLEY A: Impaired nutritive skeletal muscle blood flow in patients with chronic renal failure. Chu. Li. (1990) 79:239–245.
   Google Scholar
• JOHANSEN KL, MULLIGAN K, SCHAMBELAN M: Anabolic effects of nandrolone decanoate in patients receiving dialysis: a randomized controlled trial. JAMA (1999) 281:1275–1281.
   PubMed Web of Science ®Google Scholar
• DROMBROS NV, DIGENIS GE, SOLIMAN G, OREOPOULUS DG: steroids in the treatment of malnourished CAPD patients: a retrospective study. Pent. Dial. Int. (1994) 14:344–347.
   PubMedGoogle Scholar
• TERUEL JL, AGUILERA A, MARCEN R,NAVARRO J, GARCIA-OTERO G, ORTUSIO J: Androgen therapy for anaemia of chronic renal failure. Indications in the era. Scalar/. J. Ural. Nephrel (1995) 30:403–408.
   Google Scholar
• TERUEL JL, AGUILERA A, AVILA C, ORTUSIO J: Effects of androgen therapy on prostatic markers in hemodialyzed patients. Scan. J. Ural. Nephrel (1995) 30:129–130.
   Google Scholar
• SOLIMAN G, OREOPOULOS DG: Anabolic steroids and malnutrition in chronic renal failure. Pent. Dial. Int. (1994) 14:362–365.
   PubMedGoogle Scholar
• TERUEL JL, LASUNCION MA, RIVERA et al.: Nondrolone decanoate reduces serum lipoprotein (a) concentration in hemodialysis patients. Am. j Kid. Dis. (1997) 29:569–575.
   PubMed Web of Science ®Google Scholar
• DIEZ JJ, IGLESIAS P, AGUILERA A, BAJO MA, SELGAS R: Effects of cholinergic muscarinic blockade on growth hormone responses to growth hormone-releasing hormone in uraemic patients. Nephrel Dial. Trawl (1999) 14:1704–1709.
   PubMedGoogle Scholar
• IGLESIAS P, DIEZ JJ, FERNANDEZ-REYES MJ etal.: Recombinant human growth hormone therapy in malnourished dialysis patients: a randomized controlled study. Am. J. Kid. Dis. (1998) 32:454–463.
   Google Scholar
• ZIEGER TR, LAZARUS JM, YOUNG LS, HAKIM R, WILMORE DW: Effects of recombinat human growth hormone in adults receiving maintenance haemodialysis. J. Am. Neplirel (1991) 2:1130–1135.
   Google Scholar
• KARDINAL CG, LOPRINZI CL, SCHAID DJ et al.: A controlled trial of cyproheptidine in cancer patients with anorexia and/or cachexia. Cancer (1990) 65:2657–2662.
   PubMed Web of Science ®Google Scholar
• SHMIDT WE, CREUTZFELDT W, SCHLESER A et al.: Role of CCK in regulation of pancreaticobiliary functions and GI motility in humans: effects of loglumide. Am. J Physia (1991) 260\(pt 23):G197–G206.
   Google Scholar